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Summary
Nuclear factor kappa B (NFKB) plays an important role in multiple mye-
loma (MM), and bortezomib affects this pathway. We retrospectively analy-
sed the effect of the NFKB1 94ins/delATTG polymorphism on the
survival of 295 MM patients treated at a single centre. The median progres-
sion-free survival (PFS) was 790 (659–921) d in patients with NFKB1
homozygous insertion genotype (I/I, n = 99) and 624 (515–733) d in dele-
tion-carriers (I/D&D/D, n = 196, P = 0013). In multivariate analysis, I/I
carriers showed a favourable PFS compared to I/D&D/D with a hazard
ratio of 0622 (0457–0847), P = 0003, in addition to international staging
system (ISS) score, fluorescence in situ hybridization (FISH) risk score, age
and bortezomib treatment. I/I patients benefited more from bortezomib
treatment [PFS 902 (703–1101) and 580 (343–817), P = 0008] than
I/D&D/D patients [PFS 659 (487–831) and 488 (323–653), P = 0531]; in
addition the beneficial effect of low ISS score was not observed in the
I/D&D/D group [PFS 639 (454–824) and 650 (458–842), P = 0226], while
it was clear in I/I patients [PFS 1140 (803–1477) and 580 (408–752),
P < 0001]. We conclude that homozygous carriers of the insertion allele of
the NFKB1 94ins/delATTG polymorphism have a better prognosis and
probably benefit more from bortezomib treatment than MM patients carry-
ing the deletion allele.
Keywords: multiple myeloma, nuclear factor kappa B, bortezomib, poly-
morphism, NFKB1.
Multiple myeloma (MM) is an incurable disease affecting
mainly elderly people with an overall survival (OS) of about
5 years depending on various patient- and disease-related
factors. International scoring system (ISS) score, fluorescence
in situ hybridization (FISH) and gene expression profiling
(GEP) have become effective prognostic tools, however pre-
dicting the response of an individual patient at diagnosis is
still difficult. The current approach to treat symptomatic
myeloma is chemotherapy with a combination of novel
agents (thalidomide, bortezomib and lenalidomide), steroids
and classical chemotherapeutic drugs, followed by autologous
stem cell transplantation (ASCT) in younger and fit patients.
Bortezomib, the first in class proteasome inhibitor (PI)
received accelerated approval from the U.S. Food and Drug
Administration in relapsed refractory myeloma in 2003, and
entered into phase 3 trials in first line setting (Richardson
et al, 2003; San Miguel et al, 2008; Harousseau et al, 2010).
Currently it is standard upfront treatment in most European
countries.
Nuclear factor kappa B (NFKB) is a key player in mye-
loma. It regulates the transcription of proteins that mediate
cell cycle progression, apoptosis, drug resistance, cytokine
and chemokine production. However, the precise mechanism
of its activation and the exact role of NFKB in the pathogen-
esis of MM are yet to be fully characterized. Previous studies
have shown that NFKB is a heterodimer composed of
NFKB1 (p50) and RELA (p65), and is inactivated by its asso-
ciation with inhibitor kappa B (IkB) family inhibitors. There-
fore, NFKBIA (also termed IkB-alpha) plays a crucial role in
regulating NFKB activation. When the IkB kinase (IKK)
complex phosphorylates the NFKBIA protein, it is ubiquiti-
nated and degraded by the proteasomes, allowing transloca-
tion of NFKB1 and RELA into the nucleus where it binds to
specific DNA sequences in the promoters of target genes
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(Hideshima et al, 2009). Bortezomib and other PIs block the
proteasomal degradation of NFKBIA, thereby inhibiting the
canonical activation of the NFKB pathway. Recent studies
suggested that alternative ways of NFKB activation can also
be important in MM. Hence, inhibition of the canonical
pathway alone may be insufficient to block NFKB activity,
and NFKB inhibition may not be the only way how PIs work
in MM (Annunziata et al, 2007; Keats et al, 2007). For
example, NFKB has an important role in inflammation, and
cancers often exploit inflammatory components to improve
their survival (Aggarwal & Sung, 2011). There are several
polymorphisms within the NFKB pathway that were previ-
ously associated with the development and prognosis of vari-
ous tumours including MM (Du et al, 2011). NFKB1
94ins/delATTG is particularly interesting as it affects the
promoter activity of the NFKB1 gene (Karban et al, 2004)
and had not been tested before in MM in the context of
these novel agents. There is one study showing that MM
patients who are homozygous carriers of the wild type inser-
tion allele of this gene polymorphism may benefit more from
maintenance treatment with interferon-alpha (IFN-a, IFNA1)
(Vangsted et al, 2009). Other studies described a potential
connection between the presence of the deletion allele and
various inflammatory conditions, such as ulcerative colitis
(Borm et al, 2005) and psoriasis (Li et al, 2008). In addition,
heterozygous and homozygous carriers of the deletion allele
show increased susceptibility to colon (Lewander et al, 2007)
and small cell lung cancer (Oltulu et al, 2014). The NFKB1
94ins/delATTG polymorphism is an insertion/deletion of
four bases in the promoter region of the NFKB1 gene encod-
ing both of the NFKB1 isoforms, p50 and p105. The allele
containing the deletion is less able to bind transcription fac-
tors and produces lower transcript levels in luciferase repor-
ter systems. Consequently, carriers of the del-allele have
lower cellular levels of NFKB1 (Karban et al, 2004; Vangsted
et al, 2009).
We hypothesized that NFKB1 94ins/delATTG could have
an effect on myeloma susceptibility and treatment outcome,
especially in patients treated with PI-based regiments.
Subjects, materials and methods
Patients, clinical data, treatment and response criteria
Between January 2004 and September 2013, 295 newly diag-
nosed MM patients were treated with first line chemotherapy
at the St. Laszlo Hospital, Budapest, Hungary. This retro-
spective study evaluated the clinical parameters at diagnosis,
the types of treatment protocols and outcome parameters of
these patients. Within the bortezomib-treated group most
transplant-eligible patients were treated with bortezomib-tha-
lidomide-dexamethasone (VTD) (Cavo et al, 2012), while
melphalan-prednisolon-bortezomib (MPV) (Palumbo et al,
2010) was the standard therapy for older patients. A few
other patients had bortezomib-doxorubicin-dexamethasone
(PAD) (Oakervee et al, 2005) or bortezomib-dexamethasone
(VD) (Richardson et al, 2005) chemotherapy. The following
other, non-bortezomib containing protocols were also
applied: cyclophosphamide-thalidomide-dexamethasone
(Morgan et al, 2011), vincristin-doxorubicin-dexamethasone
(VAD) (Monconduit et al, 1986), lenalidomide-dexametha-
sone (Rajkumar et al, 2010) and melphalan-prednisolon
(MP).
Treatment continued until best response and then the
transplant-eligible patients received a high dose cyclophos-
phamide-primed stem cell mobilization, followed by high
dose melphalan-conditioned ASCT. No maintenance treat-
ment was given. All patients received antibacterial prophy-
laxis with amoxicillin and acyclovir as antiviral agent. The
median follow up was 1184 d (1019 d for the bortezomib-
treated patients and 1626 d for the non-bortezomib-treated
group).
Response criteria [complete response (CR), very good par-
tial response (VGPR), partial response (PR) no response
(NR) and progressive disease (PD)] and survival measures
[progression-free survival (PFS) and overall survival (OS)]
were defined according to published guidelines (Durie et al,
2006). Response was assessed at the end of the treatment, in
case of transplanted patients following the ASCT; 11 patients
had no response assessment due to early death.
In the healthy control group, 149 healthy blood donors
(male/female: 72/77, age: 379  109 years) were genotyped
for the presence of NFKB1 94ins/delATTG variant (Szamosi
et al, 2009).
The study was approved by the Hungarian National Ethics
Committee and participants signed informed consents.
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) was performed in
each MM cases on bone marrow slides using probes for
chromosome 13q and 17p deletion, translocation (11;14),
(4;14), (14;16) and 1q amplification. FISH results were avail-
able in 275 out of 295 patients. For the purpose of this
study, patients with t(4;14), t(14;16), 1q amplification and
del(17p) were grouped together as a high risk cohort. Previ-
ous large studies have shown that del(13q) in patients lacking
t(4;14) and del(17p) was no longer of prognostic significance
(Avet-Loiseau et al, 2007; Palumbo et al, 2014).
Genotyping
Genomic DNA was isolated from bone marrow or peripheral
blood according to the manufacturers’ recommendations
with Gentra Puragene Blood Kit (Qiagen, Crawley, UK). The
94ins/delATTG polymorphism in the NFKB1 promoter
(rs28362491) was genotyped by polymerase chain reaction
(PCR)-Van91I restriction fragment length polymorphism
(RFLP) as described (Karban et al, 2004; Szamosi et al,
2009).
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Statistical methods
Comparisons of dichotomous variables were performed by
Fisher’s exact test; continuous variables were compared with
Mann–Whitney test. Log-rank test was performed to com-
pare PFS and OS. Following univariate analysis, variables
with P values <005 in the entire cohort were included in a
Cox proportional hazards model for PFS and OS. Adjusted
hazard ratios (HR), 95% confidence intervals (CI) values,
and tests for interaction were computed. The analyses were
carried out using the SPSS (version 20.0) software package
(SPSS, Chicago, IL, USA).
Results
We analysed the NFKB1 94ins/delATTG polymorphism in
295 newly diagnosed MM patients treated at a single centre,
a large teaching hospital in Budapest. Ninety-nine patients
(336%) had homozygous insertion/insertion (I/I), 161
patients (546%) heterozygous insertion/deletion (I/D) and
35 patients (119%) had the deletion/deletion (D/D) geno-
type. Allele frequencies (AF  95% CI) observed in the total
MM patient group (392  40%), and in different MM sub-
groups (set up by age, ISS score, FISH and PI treatment)
were not different from healthy controls (386  56%). Due
the low case number in the D/D group the D/D and I/D
subgroups were merged as deletion carriers.
Study population
Patient characteristics are shown in Table I. Among the 295
newly diagnosed MM patients, 148 were males and 147
females, with a median age of 60 (27–84) years. The majority
of patients had either IgG (58%) or IgA (20%) myeloma and
17% had light chain (LC) disease. Among the remaining 14
(5%) patients there were 3 IgD, 2 IgM, 1 IgE and 8 true
non-secretory diseases. ISS was calculated in each case at
diagnosis, with 32, 26 and 42% of the patients having an ISS
score of 1, 2 and 3 respectively. According to our pre-defined
FISH risk stratification, 74 patients (27%) were in the high-
risk and 201 (73%) in the low-risk groups.
One hundred and seventy-four patients [90 males and 84
females; median age: 60 (28–84) years] had bortezomib-based
treatment and 121 [58 males and 63 females; median age: 60
(27–84) years] had other, non-bortezomib containing proto-
cols. The treatment decision was at the discretion of the
treating physician. Within the bortezomib-treated cohort, 88
patients received VTD, 33 received PAD, 45 MPV and eight
VD treatment. The majority (83%) of the VTD- and PAD-
treated patients also received ASCT. In the non-bortezomib
treated group, the majority of patients had either thalido-
mide-based therapy (54 patients) or VAD protocol (43
patients) and almost half of them (48% thalidomide-treated
and 46% VAD-treated patients) received ASCT consolida-
tion. Only four patients had lenalidomide-dexamethasone
and 20 received MP. Treatment continued until best
response or intolerable toxicities. Sixty-three per cent of the
bortezomib-treated patients received ASCT whereas ASCT
frequency was lower (39%) in the non-bortezomib group,
reflecting the fact that, from 2008, VTD became the preferred
induction in transplant candidates, while oral protocols were
more feasible for frailer patients in our hospital. The median
age of the transplanted and non-transplanted patients was 57
and 67, respectively (P < 0001).
Patients in the I/I group were significantly older than in
the I/D&D/D group [median age 63 (range: 32–84) years vs.
60 (range: 27–84) years, P = 0049] but apart from this, there
was no significant difference in the distribution of disease
Table I. Patients’ characteristics according to their NFKB1 94ins/
delATTG genotypes.
All I/I I/D&D/D P
n (%) 295 99 196
Sex
Male 148 (502) 52 (525) 96 (490) 0622
Female 147 (498) 47 (475) 100 (510)
Median age, years
(range)
60 (27–84) 63 (32–84) 60 (27–84) 0049
ISS score
1 + 2 158 (585) 51 (567) 107 (594) 0695
3 112 (415) 39 (433) 73 (406)
FISH
Low risk 201 (731) 67 (736) 134 (728) 1000
High risk* 74 (269) 24 (264) 50 (272)
Bortezomib
Yes 174 (59) 64 (646) 110 (561) 0170
No 121 (41) 35 (354) 86 (439)
Chemotherapy
VTD 88 (298) 33 (333) 55 (281) 0350
PAD 33 (112) 11 (111) 22 (112) 1000
MPV 45 (153) 19 (192) 26 (133) 0230
VD 8 (27) 1 (10) 7 (36) 0275
Thal 54 (183) 16 (162) 38 (194) 0528
Len 4 (14) 1 (10) 3 (15) 10
VAD 43 (146) 11 (111) 32 (163) 0295
MP 20 (68) 7 (71) 13 (66) 10
ASCT
Yes 157 (532) 52 (525) 105 (536) 0902
No 138 (468) 47 (475) 91 (464)
ASCT, autologous stem cell transplantation; D/D, homozygous dele-
tion; FISH, fluorescence in situ hybridization; I/D heterozygous
insertion plus deletion; I/I, homozygous insertion; ISS, International
scoring system; Len, lenalidomide-based; MP, melphalan, predniso-
lone; MPV, melphalan, prednisolone, bortezomib; PAD, bortezomib,
doxorubicin, dexamethasone; Thal, thalidomide-based without
bortezomib; VAD, vincristine, doxorubicin, dexamethasone; VD,
bortezomib, dexamethasone; VTD, bortezomib, thalidomide, dexa-
methasone.
Significant P values are in bold.
*FISH high risk: t(4;14), t(14;16), del 17p and 1q amplification; low
risk: all others.
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characteristics and prognostic markers across the different
NFKB1 94ins/delATTG genotypes (Table I).
The effect of conventional prognostic factors on response
and survival
In order to analyse the impact of variations in NFKB1 geno-
type on therapy, we first looked at the effect of conventional
risk factors (age, ISS score and FISH) on the response, PFS
and OS (Table SI).
The median PFS and OS for the entire cohort (n = 295)
was 670  436 and 1966  1089 d. Age at diagnosis had a
significant effect on PFS and OS. The median PFS in patients
aged below and above 60 years was 768 and 582 d
(P = 0009), respectively, and the median OS was 2304 and
1888 d (P = 0016) respectively. Using 70 years of age as a
cut-off point, PFS was 739 and 458 d (P < 0001), and the
OS 2120 and 1029 d, respectively (P < 0001). ISS score was
also confirmed as a significant factor in survival. PFS in
patients with an ISS score of 1, 2 and 3 were 761, 783 and
600 d (P = 0003), and OS in the same groups were 3136,
2304 and 1255 d, respectively (P < 0001) (Table SI, in fur-
ther analyses ISS scores 1 and 2 were merged).
Among the tested FISH abnormalities, del(17p) and
t(4;14) had significant impact on PFS. In case of del(17p)
(n = 6), the median PFS was only 136 d compared to 670 d
of patients without the deletion (P < 0001) and the OS was
603 d and 1962 d, respectively (P = 0054). For t(4;14), the
median PFS was only 488 d compared to 701 d for patients
without the deletion (P = 0026), however, there was no dif-
ference in OS (1683 d and 1966 d, respectively, P = 0643).
In addition, there was a trend for worse PFS and OS in
patients with 1q amplification at diagnosis (P = 0068 and
0089). Using the pre-defined FISH risk stratification, we
observed a significant difference in PFS but not in OS [PFS
545 d in high and 727 d in low risk FISH (P = 0002); OS
1611 d in high and 2099 d in low risk FISH patients
(P = 0115)]. Other factors, such as immunoglobulin subtype
and sex, had no effect on either PFS or OS and therefore
were not included in the multivariate and subgroup analyses.
As expected, patients receiving bortezomib-based therapy
had a superior outcome compared to other patients, with a
significant difference for PFS (739 vs. 578 d, P = 0028), but
not OS (P = 0217); patients that underwent ASCT fared
significantly better (PFS 893 vs. 365 d, P < 0001; OS 2386
vs. 1530 d, P < 0002).
The effect of the NFKB1 94ins/delATTG polymorphism
on the quality of response to treatment
In the whole cohort, there was no difference between the
NFKB1 subgroups in terms of quality of response. The pro-
portion of CRs, VGPRs, PRs and NR/PDs were 375%,
167%, 365%, 94% in the I/I group and 399%, 181%,
282%, 138% in the I/D&D/D group, respectively, with no
significant difference. Bortezomib-treated patients showed
significantly deeper responses than the other groups: CRs,
VGPRs, PRs and NR/PDs were 535 vs. 175% (P < 0001),
194 vs. 149% (P = 0346), 241 vs. 412% (P = 0003) and
29 vs. 263% (P < 0001) respectively.
In the bortezomib-treated group the NFKB1 genotypes
were distributed evenly across the four response categories
(Table II), nevertheless when we compared the number of
treatment cycles required by NFKB1 I/I and I/D&D/D
patients to reach their best responses, I/D&D/D patients
required significantly more cycles of chemotherapy to reach
their best responses. While patients with homozygous inser-
tion (I/I genotype) needed 378 cycles on average, deletion
carriers (I/D&D/D genotypes) required 432 (P = 0008).
This difference was also significant between I/I and I/D&D/D
patients who achieved CR due to the higher number of quick
responders (P = 0012, Table II).
The effect of the NFKB1 94ins/delATTG polymorphism
on survival of the whole cohort
When we analysed the effect of the NFKB1 94ins/delATTG
polymorphism on survival, we demonstrated that the pres-
ence of at least one D allele had a significant effect on PFS.
The median PFS was 670 d in the entire cohort, 790 in the
Table II. Best responses and average number of bortezomib cycles needed to reach the best response in upfront bortezomib-treated MM patients
according to NFKB1 genotype. Four bortezomib-treated patients were not assessed for response due to early death.
Best response
All I/I I/D & D/D
P (cycle number)n % Cycles n % Cycles n % Cycles
CR 91 535 408 35 556 371 56 523 430 0012
VGPR 33 194 394 10 159 380 23 215 400 0305
PR 41 241 427 17 270 376 24 224 463 0243
NR, PD 5 29 480 1 16 60 4 37 450 0400
Total 170 1000 412 63 1000 378 107 1000 432 0008
CR, complete response; D/D, homozygous deletion; I/D heterozygous insertion plus deletion; I/I, homozygous insertion; NR, no response; PD,
progressive disease; PR, partial response; VGPR, very good partial response.
Significant P values are in bold.
Patients in the I/D&D/D group required significantly more cycles of chemotherapy to reach their best responses.
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I/I group and 624 in the I/D&D/D group (P = 0013;
Fig 1A). In terms of OS there was no significant difference:
the OS was 1931 and 1966 d in the I/I and I/D&D/D groups
(P = 0535), and 1966 in the whole cohort (Table SI).
Multivariate analysis (Cox proportional hazard model)
showed that, in addition to age, ISS score, FISH and bortezo-
mib treatment, the presence of NFKB1 genotypes I/D&D/D
was an independent risk factor for PFS in the whole cohort,
I/I 790 (659–921)
I/D&D/D 624 (515–733)
ISS1+2 - I/I 1140 (803–1477)
ISS1+2 - I/D&D/D 639 (454–824)
ISS3 - I/I 580 (408–752)
ISS3 - I/D&D/D 650 (458–842)
PF
S
syadsyad
PF
S
I/I n = 99
I/D&D/D
n = 196
ISS1+2-I/I 
n = 51
ISS1+2-I/D&D/D 
n = 107
ISS3-I/I
n = 39
ISS3-I/D&D/D
n = 73
P = 0·013
P = 0·991
P = 0·001
FISH LR-I/I
n = 67
FISH LR - I/I 920 (659–1180)
FISH LR - I/D&D/D 642 (476–808)
FISH HR - I/I 670 (381–959)
FISH HR - I/D&D/D 480 (380–580)
PF
S
syadsyad
PF
S
FISH LR-I/D&D/D 
n = 134
FISH HR-I/I
n = 24
FISH HR-I/D&D/D
n = 50
bor-I/I n = 64
bor-I/D&D/D
n = 110
no bor-I/I
n = 35
no bor-I/D&D/D
n = 86
P = 0·142
P = 0·011
P = 0·023
P = 0·023
bor - I/I 902 (703–1101)
bor - I/D&D/D 659 (487–831)
no bor - I/I 580 (343–817)
no bor - I/D&D/D 488 (323–653)
P = 0·928
P = 0·003
P = 0·531
P = 0·008
P = 0·226
P < 0·001
(A) (B) 
(C) (D)
Fig 1. Comparisons of progression-free survival between NFKB1 94ins/delATTG I/I genotype vs. deletion carriers (I/D and D/D combined).
PFS for all patients (A); in subgroups according to ISS score (1 + 2 and 3) (B); in subgroups with low risk (LR) and high risk (HR) FISH abnor-
malities (C); and in subgroups according to bortezomib treatment (D). Below the graphs, median PFS (95% CI) and P-values calculated by
paired Kaplan–Meier analysis for each subgroup are shown. There was a significant survival advantage for NFKB1 I/I compared to I/D&D/D
patients in the whole cohort, in each subgroup with good prognosis and in the bortezomib-treated subgroup. Also, the benefit generally conferred
by low ISS score and bortezomib treatment was significantly more pronounced in the NFKB1 I/I cohort and non-significant in I/D&D/D patients.
bor, bortezomib; CI, confidence interval; D/D, homozygous deletion; FISH, fluorescence in situ hybridization; HR, high risk; I/D heterozygous
insertion plus deletion; I/I, homozygous insertion; ISS, International scoring system; LR, low risk; PFS, progression-free survival.
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and also, in some of the subgroups (Fig 2). Similarly, the use
of bortezomib was found to be an independent protective
factor in the Cox model (Table SII). In terms of OS, only
age and ISS score were significant independent risk factors;
FISH and NFKB1 were not (Table SII).
Before further subgroup analyses, we performed statistical
tests for interaction between NFKB1 genotype and the other
factors involved in the Cox analysis for PFS. This showed a sta-
tistically significant interaction for the NFKB1 genotype with
ISS score but not with FISH and bortezomib therapy (Fig 2).
The impact of the NFKB1 94ins/delATTG
polymorphism on survival in different subgroups
We observed a significant PFS benefit for NFKB1 I/I patients
in all subgroups with favourable risk features (Fig 1B,C).
Within the subgroup with ISS score 1 + 2, the median PFS of
the I/I vs. I/D&D/D patients was 1140 vs. 639 d (P = 0001)
and it was 580 vs. 650 d (P = 0991) in the subgroup with ISS
score 3 (Fig 1B). There was no significant difference between
the OS of the same groups [2565 vs. 2465 (P = 0646) and
1075 vs. 1269 (P = 0395) respectively] (Table SI).
Within the low risk FISH group, we observed a significant
difference between the PFS of the I/I and I/D&D/D patients
(920 vs. 642 d, P = 0011), which was not significant among
the high risk patients (670 vs. 480 d, P = 0142) (Fig 1C).
There was no significant difference between the OS of the I/I
and I/D&D/D carriers in either FISH subgroup (Table SI).
Within the bortezomib-treated cohort, the difference
between the two genetic subgroups was highly significant. In
this group (n = 174), the PFS was 902 in the I/I group and
659 in the I/D&D/D group (P = 0003). Importantly, there
was no similar difference between the PFS of the two NFKB1
groups within the non-bortezomib treated cohort (n = 121)
(Fig 1D).
Although we attempted to stratify patients according to
the eight different treatment protocols applied in this study,
we concluded that most of the groups were not large enough
to draw any meaningful conclusions regarding the survival of
the involved I/I and I/D&D/D patients separately. The largest
group was the VTD-treated patients (n = 88, followed by
ASCT n = 78), for whom the PFS was 1154 (I/I) and 727 d
(I/D&D/D) in the two genetic groups (P = 0002), with the
median OS not reached in the I/I group and 1962 d in the
I/D&D/D group (P = 0014). We could not demonstrate a
significant difference in PFS in any of the other treatment
groups (data not shown).
We analysed the patient groups separately according to
NFKB1 I/I and I/D&D/D genotypes. Interestingly, while in
the subgroup of NFKB1 I/I carriers, low ISS score, low risk
FISH and the presence of bortezomib treatment showed sig-
nificant effects on PFS (protective factors with decreased haz-
ard ratio), in the I/D&D/D carrier subgroup, neither ISS
score nor bortezomib treatment had a significant impact on
survival (Fig 1B–D).
Discussion
Myeloma susceptibility
There was no significant difference in the allele frequencies
of the NFKB1 94ins/delATTG polymorphism between our
1·274) (0·472−0·775 0·315 Non-bortezomib
0·803) (0·358−0·536 0·002Bortezomib
1·055) (0·317−0·578 0·074 FISH high risk
0·867) (0·414−0·599 0·007FISH low risk
1·248) (0·525−0·809 0·337 ISS 3
0·700) (0·277−0·441 0·001ISS 1+2
(95·0% CI)HRPSubgroups
p for interaction 0·027 
p for interaction 0·846 
p for interaction 0·522 
1·0 1·2 0·8 0·6 0·4 0·2 
0·847) (0·457−0·622 0·003All patients 
Fig 2. Risk factors in subgroups of patients. Hazard ratio (HR, diamonds) with 95% confidence intervals (horizontal lines) calculated by multi-
variate analysis (Cox-model) for PFS and NFKB1 94ins/delATTG genotype in various subgroups adjusted to age, ISS score, FISH and bortezo-
mib treatment. P values of interaction testing between NFKB genotype and the respective covariates are inserted below the symbols for ISS score,
FISH results and the use of bortezomib treatment respectively. Multivariate analysis identified the NFKB1 polymorphism as an independent prog-
nostic factor for PFS in ISS low risk, FISH low risk and bortezomib-treated patients. Statistical test for interaction was significant between NFKB1
and ISS score but was not significant between NFKB1 and either FISH score or bortezomib treatment. FISH high risk: t(4;14), t(14;16), del 17p
and 1q amplification; low risk: all others. CI, confidence interval; D/D, homozygous deletion; FISH, fluorescence in situ hybridization; HR, hazard
ratio; I/D heterozygous insertion plus deletion; I/I, homozygous insertion; ISS, International scoring system; PFS, progression-free survival.
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patients and healthy Hungarian individuals, thus, in our
cohort there was no association between this polymorphism
and the risk of myeloma. Other groups described an
increased frequency of various malignancies in patients with
NFKB1 94ins/delATTG ID and DD genotypes, including
colon cancer (Lewander et al, 2007), small cell lung cancer
(Oltulu et al, 2014), bladder (Li et al, 2013) and prostate
cancer (Zhang et al, 2009). On the other hand, in nasopha-
ryngeal cancer Zhou et al (2009) found increased risk in the
I/I group. To our knowledge, this is the first publication that
compares NFKB1 94ins/delATTG allele frequencies between
MM patients and normal individuals.
NFKB1 encodes the genes for the p50 and p105 NFKB1
isoforms, ubiquitous transcription regulators important for
multiple diseases associated with inflammation and immu-
nity. Karban et al (2004) found that carriers of NFKB1
94ins/delATTG D allele showed significantly reduced pro-
moter activity in vitro, which was particularly pronounced
following 24 h of exposure to lipopolysaccharide extract. The
exact connection between these phenomena and the
increased susceptibility to colitis in patients with the NFKB1
D allele was not clear, but they hypothesized that poor acti-
vation of the NFKB pathway may weaken the normal cellular
defences against intestinal bacteria that may allow bacteria
crossing the intestinal mucosa not to be properly cleared by
the immune system, and hence contribute to on-going intes-
tinal inflammation (Karban et al, 2004).
Regarding cancer susceptibility, it can be concluded that
previous studies showed conflicting results. NFKB can pro-
mote carcinogenesis by enhancing proliferation and angio-
genesis, suppressing apoptosis and immune response (Karin,
2006). Recently Zou et al (2011) suggested that the deletion
allele is protective for cancer susceptibility among Asians and
is a risk allele in Caucasians.
Response to chemotherapy and survival
We observed a longer PFS among patients carrying NFKB1
94ins/delATTG I/I in comparison to those with I/D&D/D.
This difference in PFS was highly significant, and even more
pronounced in subgroups with better prognosis, such as ISS
score 1 and 2 and low risk FISH group. It is important to
mention that I/I patients fared better even if they were signif-
icantly older than I/D&D/D carriers.
The differences increased further when we focused on the
bortezomib-treated subgroup, especially the VTD-treated
patients and those having had ASCT consolidation. However,
we have to keep in mind that treatment choice in this retro-
spective study was not independent of other factors. From
2008, VTD was the preferred induction in transplant eligible
patients and the majority of the VTD-treated patients there-
fore had ASCT consolidation as well. Also, early death is a
well-known complication in myeloma, with a higher preva-
lence in high risk patients, who therefore have a lower
chance of surviving long enough to receive ASCT. Based on
our results, NFKB1 94ins/delATTG I/I seems to have a
stronger effect on the survival of myeloma patients with bet-
ter prognosis according to ISS score and FISH and those
who had bortezomib treatment.
It is interesting and may help to explain this phenomenon
that, among the 174 bortezomib-treated patients there was a
significant correlation between the NFKB1 subgroup and the
number of bortezomib cycles these patients required before
reaching their best responses. Although the number of
patients reaching CR and VGPR were similar, I/I patients
typically required <4 cycles of chemotherapy whereas the
I/D&D/D patients needed more.
It is also important to note that while the NFKB1 I/I
genotype cohort showed a clear survival advantage in ISS
score 1 + 2 and low risk FISH patients and those treated
with bortezomib, the I/D&D/D patients seemed to have a
poor prognosis regardless of ISS score and did not seem to
benefit significantly from bortezomib treatment.
Multivariate analysis identified NFKB1 I/I genotype and
bortezomib treatment as significant independent protective
factors. However we were not able to demonstrate a statisti-
cal interaction between bortezomib treatment and NFKB1
genotype using the Cox model. At the same time, with uni-
variate analysis showed a significant, 8-month PFS advantage
for NFKB1 I/I patients compared to I/D&D/D carriers within
the bortezomib-treated group with no similar difference
among the non-bortezomib treated patients. We believe this
is clinically substantial. We speculate that the lack of statisti-
cal interaction between bortezomib treatment and NFKB1
genotype is due to the following reasons. (i) The relatively
low case numbers in some of the subgroups, (ii) the different
follow-up times in non-bortezomib and bortezomib-treated
patients, and, most importantly, (iii) the fact that this is a
retrospective non-randomized study where the decision
between bortezomib and non-bortezomib protocols may have
been biased in many cases, resulting in an increased number
of low risk ISS and FISH patients in the non-bortezomib
subgroup.
The lack of significant difference in OS is probably partly
due to the fact that the follow-up period was relatively short.
During the disease course a typical myeloma patient is
exposed to various combination chemotherapies, bortezomib
being only one of them. If we accept that the beneficial effect
of NFKB1 polymorphism is due to interaction with bortezo-
mib and not with other treatments, then this may explain
why we failed to demonstrate a clear OS benefit in our
patients.
The situation within the non-bortezomib treated cohort is
more complex. As a group, these patients failed to show sur-
vival benefit in either NFKB1 genotype subgroup. In a retro-
spective study, Vangsted et al (2009) analysed the effect of
NFKB1 94ins/delATTG polymorphism on the survival of
myeloma patients treated with VAD induction and ASCT
with or without IFN-a maintenance. The main finding was
that, within the IFN-a treated group, the presence of the I/I
NFKB1 94ins/delATTG Polymorphism in Myeloma
ª 2014 John Wiley & Sons Ltd 685
British Journal of Haematology, 2015, 168, 679–688
genotype provided the patients with a significant survival
benefit [time to treatment failure (TTF) 499 (I/I) vs. 344
(I/D&D/D) months, OS not reached in the I/I group after
120 months vs. 744 months in the I/D&D/D group,
P = 009 and 0002] (Lenhoff et al, 2000; Vangsted et al,
2009). This difference was only observable in the IFN-a-trea-
ted cohort, while in the no maintenance group, I/I patients
actually seemed to have a slightly (although not significantly)
worse outcome. The authors speculated that this selective
effect of IFN-a maintenance on homozygous I/I allele carri-
ers indicates that the effect of IFN-a depends on the avail-
ability of NFKB, which is essential for both the innate and
adaptive immune systems (Vangsted et al, 2009).
NFKB1 94ins/delATTG polymorphism is an insertion/
deletion polymorphism of four bases in the promoter region
of the NFKB1 affecting its capability to bind transcription
factors. As a result, carriers of the D allele have lower levels
of NFKB1 (Karban et al, 2004) and may have a different
response to various transcription factors. Although bortezo-
mib has many potential ways in which it can interact with
the proliferation of MM cells, the main mechanism of action
is probably through the NFKBIA-NFKB pathway. Our
hypothesis is that, due to the higher expression of NFKB1 in
homozygous carriers of the I/I allele, myeloma cells could be
more dependent on this pathway, and therefore its blocking
could have a stronger effect on them compared to patients
with I/D&D/D genotypes with lower NFKB1 levels.
The observed positive effect of the I/I allele was the
strongest and most unequivocal among the VTD-treated
patients, who also benefited from the immunomodulatory
effect of thalidomide and the majority of whom received
additional ASCT. It is possible that this difference is at least
partially related to the effect of either the thalidomide or the
ASCT or both. However, there was no significant difference
between the two NFKB1 genotypes in either patients having
thalidomide treatment without bortezomib or in the group
of ASCT-treated patients without bortezomib in the induc-
tion. Still, we cannot exclude the possibility that the observed
survival benefit in the I/I patients is somehow related to the
combined effect of bortezomib, thalidomide and ASCT, and
therefore mainly affects VTD-treated patients having had
ASCT. Of note, when analysing the MPV-treated group, the
outcome of I/I patients compared to I/D&D/D carriers was
not significantly different. On the other hand, the median
age of the VTD and MPV patients was 58 and 73 years,
respectively and, within the MPV-treated cohort, I/I patients
were older than I/D&D/D carriers. As age is a very strong
predictor of short survival, we think that the main factor
behind the fact that the NFKB1 polymorphism had virtually
no effect on the survival of the MPV-treated patients was
that old age suppressed the beneficial effect of the I/I geno-
type among these patients.
The effect of proteasome inhibition on the NFKB pathway
is far from clear. Recently, investigators found that, similarly
to other chemotherapeutic agents and radiotherapy,
paradoxically bortezomib can also induce canonical NFKB
activation via IkB downregulation. This phenomenon was
recently described in endometrial cancer (Dolcet et al, 2006),
gastrointestinal stromal tumour (Bauer et al, 2010) and also
in myeloma (Hideshima et al, 2009), suggesting that bortezo-
mib-induced cytotoxicity cannot be fully attributed to inhibi-
tion of the canonical NFKB activity in MM cells. Moreover,
a previous study has demonstrated a highly activated nonca-
nonical pathway in primary MM cells, and it is possible that
bortezomib blocks noncanonical NFKB activity, due to inhi-
bition of proteasome-dependent NFKB2/p100 conversion
into the active p52 isoform (Keats et al, 2007). Clearly this
effect could be different in patients with or without the D
allele and therefore to understand exactly how NFKB1
94ins/delATTG genetic variants affect the survival of MM
cells, it would be essential to investigate its effect on both
canonical and noncanonical pathways of NFKB activation.
In conclusion, our data indicate that, patients who are
homozygous carriers of the wild type insertion allele of the
NFKB1 94ins/delATTG polymorphism have better outcome
compared to patients carrying the variant deletion allele. This
survival advantage is more pronounced in patients with low
risk MM. Based on our data, homozygous insertion type
patients may benefit more from treatment with VTD and
ASCT. Therefore this polymorphism may be a prognostic
marker in MM patients having first line treatment. Further
studies are needed to confirm this association in independent
cohorts and to clarify the molecular background of this effect
on bortezomib therapy in MM.
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